Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The RX source does not recommend the combination below CrCl 30. The NIH panel separately permits the chronic-HD setting and describes uncertainty outside that setting.
Before applying: Review the NIH row and applicable current label with an HIV specialist. This is a documented difference, not agreement between independent validators.
Also check: NIH chronic-HD exception differs from RX restriction
Rxlist source
GlobalRPh RX List - Symtuza
Product / population
Fixed combination; selected adult renal guidance. Do not substitute single-component TAF guidance.
Renal measure
Estimated CrCl, mL/min.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
No renal dosage adjustment is required when estimated CrCl is at least 30 mL/min. This fixed combination is not recommended below 30 mL/min. Check serum creatinine, estimated CrCl, urine glucose and urine protein before and during treatment; also assess serum phosphorus in chronic kidney disease. Cobicistat can increase serum creatinine and lower estimated CrCl by inhibiting tubular creatinine secretion without reducing actual glomerular filtration.
Source revision: Revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
guideline vs label
NIH chronic-HD exception differs from RX restriction
The RX source does not recommend the combination below CrCl 30. The NIH panel separately permits the chronic-HD setting and describes uncertainty outside that setting.
How to use this: Review the NIH row and applicable current label with an HIV specialist. This is a documented difference, not agreement between independent validators.
Source difference identified; final patient-specific adjudication required.
Go directly to the relevant source section
Renal dosing and precautions
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Symtuza
Fixed combination; selected adult renal guidance. Do not substitute single-component TAF guidance.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Fixed combination; selected adult renal guidance. Do not substitute single-component TAF guidance.
Renal method: Estimated CrCl, mL/min. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No renal dosage adjustment is required when estimated CrCl is at least 30 mL/min. This fixed combination is not recommended below 30 mL/min. Check serum creatinine, estimated CrCl, urine glucose and urine protein before and during treatment; also assess serum phosphorus in chronic kidney disease. Cobicistat can increase serum creatinine and lower estimated CrCl by inhibiting tubular creatinine secretion without reducing actual glomerular filtration.
RDM33-rxlist-darunavir-cobicistat-emtricitabine-taf-symtuza-C1 · Source locator: Dosage and administration; use in specific populations: renal impairment; renal monitoring warnings.
NIH ClinicalInfo HIV Guidelines · Adult SYMTUZA fixed combination; panel recommendations, including explicitly identified uncertainty.
Renal method: CrCl, mL/min; chronic hemodialysis considered separately. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
SYMTUZA: one tablet orally daily with food. The panel does not recommend use at CrCl 15-29 or below 15 without hemodialysis. It notes insufficient evidence about full-dose emtricitabine below 30, although some panel members use it at 15-29 to retain the combination. On chronic hemodialysis, no adjustment is recommended; give after dialysis on dialysis days. That specialist exception must not be extended to all severe impairment.
RDM33-professional-darunavir-cobicistat-emtricitabine-taf-symtuza-C1 · Source locator: Appendix B, named product row.
Source-specific limits
Expert-panel recommendations and FDA-label recommendations can differ. This is not a second independent trial.
Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.